Is rasagiline as effective as selegiline a...
Reformed-Redan
15 May 2012
I'd rather be taking rasagiline for life enhancing effects rather than selgiline. Selegiline has methamphetamine metabolites that caused some member from a fitness forum to go to jail for a false positive. I don't want to be in that kind of unforeseeable situation. So, is rasagiline as effective as selegiline at increasing lifespan? Thx.
Baten
15 May 2012
Selegiline has methamphetamine metabolites that caused some member from a fitness forum to go to jail for a false positive.
Wait, what? I thought these metabolites were at the 0.01% level. Pretty disturbing if that really happened.
Climactic
01 Mar 2013
It makes no sense to go to jail for metabolites. It's not the same as possession of meth. He must've been doing other things wrong.
medievil
01 Mar 2013
If i remember correctly he was on probation and if he fucked that he would automatically go back, bit silly to take deprenyl then if you ask me tough.It makes no sense to go to jail for metabolites. It's not the same as possession of meth. He must've been doing other things wrong.
lol cant stop laughing at randomly going to jail for metabolites as it seems the op put it, imagine if thats true.
LexLux
23 Feb 2014
If i remember correctly he was on probation and if he fucked that he would automatically go back, bit silly to take deprenyl then if you ask me tough.It makes no sense to go to jail for metabolites. It's not the same as possession of meth. He must've been doing other things wrong.
lol cant stop laughing at randomly going to jail for metabolites as it seems the op put it, imagine if thats true.
funny indeed, sometimes I come across posts on this forum that have me dissolving into laughter. no one answered the OP though...
LexLux
23 Feb 2014
New study showing that it seems to be well tolerated
"Among the most frequently reported adverse effects for rasagiline as monotherapy are headache, dizziness, and insomnia. Depression, dizziness, somnolence, and other sleep disorders are reported when used in combination therapy. Our analysis demonstrates that the most frequently reported adverse effects in trials did not occur more often with rasagiline than placebo. In conclusion, rasagiline is a well-tolerated MAO-B inhibitor that may help to achieve the desired level of clinical benefit in Parkinson's disease."
http://www.ncbi.nlm....pubmed/23634791
Edited by LexLux, 23 February 2014 - 11:11 AM.
"Among the most frequently reported adverse effects for rasagiline as monotherapy are headache, dizziness, and insomnia. Depression, dizziness, somnolence, and other sleep disorders are reported when used in combination therapy. Our analysis demonstrates that the most frequently reported adverse effects in trials did not occur more often with rasagiline than placebo. In conclusion, rasagiline is a well-tolerated MAO-B inhibitor that may help to achieve the desired level of clinical benefit in Parkinson's disease."
http://www.ncbi.nlm....pubmed/23634791
Edited by LexLux, 23 February 2014 - 11:11 AM.
LexLux
23 Feb 2014
2013 Study - Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease (http://www.ncbi.nlm....pubmed/23196982)
The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of L-amphetamine and L-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson's disease on a stable drug therapy. 30 patients, who took 7.5 mg selegiline daily for at least 3 months, were switched to 1 mg rasagiline. Then they were followed over an interval of 4 months. The remaining drug therapy remained stable. This changeover was safe and well tolerated. L-Amphetamine and L-methamphetamine only appeared during selegiline treatment. Motor behavior, motor complications, mood and sleep improved during rasagiline administration. Amphetamine-like derivatives of selegiline could contribute to sleep disturbances, which may be involved in worsening of mood. Motor behavior and motor complications probably became better due to the additional glutamate receptor antagonizing properties of rasagiline in this open label study.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(MAO) inhibitors continue to hold a niche in psychiatry (http://www.ncbi.nlm....pubmed/23410524)
Although not used as extensively as other antidepressants for the treatment of depression, the monoamine oxidase (MAO) inhibitors continue to hold a niche in psychiatry and to have a relatively broad spectrum with regard to treatment of psychiatric and neurological disorders.
Experimental and clinical research on MAO inhibitors has been expanding in the past few years, primarily because of exciting findings indicating that these drugs have neuroprotective properties (often independently of their ability to inhibit MAO). The non-selective and irreversible MAO inhibitors tranylcypromine (TCP) and phenelzine (PLZ) have demonstrated neuroprotective properties in numerous studies targeting elements of apoptotic cascades and neurogenesis.
l-Deprenyl and rasagiline, both selective MAO-B inhibitors, are used in the management of Parkinson's disease, but these drugs may be useful in the treatment of other neurodegenerative disorders given that they demonstrate neuroprotective/neurorescue properties in a wide variety of models in vitro and in vivo. Although the focus of studies on the involvement of MAO inhibitors in neuroprotection has been on MAO-B inhibitors, there is a growing body of evidence demonstrating that MAO-A inhibitors may also have neuroprotective properties.
In addition to MAO inhibition, PLZ also inhibits primary amine oxidase (PrAO), an enzyme implicated in the etiology of Alzheimer's disease, diabetes and cardiovascular disease. These multifaceted aspects of amine oxidase inhibitors and some of their metabolites are reviewed herein.
The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of L-amphetamine and L-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson's disease on a stable drug therapy. 30 patients, who took 7.5 mg selegiline daily for at least 3 months, were switched to 1 mg rasagiline. Then they were followed over an interval of 4 months. The remaining drug therapy remained stable. This changeover was safe and well tolerated. L-Amphetamine and L-methamphetamine only appeared during selegiline treatment. Motor behavior, motor complications, mood and sleep improved during rasagiline administration. Amphetamine-like derivatives of selegiline could contribute to sleep disturbances, which may be involved in worsening of mood. Motor behavior and motor complications probably became better due to the additional glutamate receptor antagonizing properties of rasagiline in this open label study.
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
(MAO) inhibitors continue to hold a niche in psychiatry (http://www.ncbi.nlm....pubmed/23410524)
Although not used as extensively as other antidepressants for the treatment of depression, the monoamine oxidase (MAO) inhibitors continue to hold a niche in psychiatry and to have a relatively broad spectrum with regard to treatment of psychiatric and neurological disorders.
Experimental and clinical research on MAO inhibitors has been expanding in the past few years, primarily because of exciting findings indicating that these drugs have neuroprotective properties (often independently of their ability to inhibit MAO). The non-selective and irreversible MAO inhibitors tranylcypromine (TCP) and phenelzine (PLZ) have demonstrated neuroprotective properties in numerous studies targeting elements of apoptotic cascades and neurogenesis.
l-Deprenyl and rasagiline, both selective MAO-B inhibitors, are used in the management of Parkinson's disease, but these drugs may be useful in the treatment of other neurodegenerative disorders given that they demonstrate neuroprotective/neurorescue properties in a wide variety of models in vitro and in vivo. Although the focus of studies on the involvement of MAO inhibitors in neuroprotection has been on MAO-B inhibitors, there is a growing body of evidence demonstrating that MAO-A inhibitors may also have neuroprotective properties.
In addition to MAO inhibition, PLZ also inhibits primary amine oxidase (PrAO), an enzyme implicated in the etiology of Alzheimer's disease, diabetes and cardiovascular disease. These multifaceted aspects of amine oxidase inhibitors and some of their metabolites are reviewed herein.
